Abstract
Helicobacter pylori (H. pylori) infects the stomach of more than 50% of humans and causes chronic gastritis in most infected individuals. H. pylori has developed mechanisms to survive the harsh gastric environment. In the host infected with H. pylori, various immune cells infiltrate into the infected gastric mucosa and then severe inflammatory responses occur. This severe inflammation, however, is not able to clear H. pylori and the process may contribute to the associated disease pathogenesis. Toll-like receptor 2 (TLR2) and Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) might be essential for activation of innate immunity against H. pylori infections. Type 1 helper T cells and regulatory T cells induced in stomach and Peyers patches play an important role in the associated chronic inflammation. Recently, vaccines targeting various factors associated with H. pylori infection have been developed. This review provides information on the mechanisms of the host immune system response against H. pylori infections and the characteristics of H. pylori that enable it to evade host defenses.
Keywords: Gastritis, Helicobacter pylori, immunity, inflammation, Peyer's patch, vaccine
Current Chemical Biology
Title: Mucosal Immune Regulation and Vaccines for Helicobacter-associated Gastritis
Volume: 4 Issue: 3
Author(s): Yasuhisa Ano, Hirokazu Tsubone, Akikazu Sakudo and Daisuke Fujiwara
Affiliation:
Keywords: Gastritis, Helicobacter pylori, immunity, inflammation, Peyer's patch, vaccine
Abstract: Helicobacter pylori (H. pylori) infects the stomach of more than 50% of humans and causes chronic gastritis in most infected individuals. H. pylori has developed mechanisms to survive the harsh gastric environment. In the host infected with H. pylori, various immune cells infiltrate into the infected gastric mucosa and then severe inflammatory responses occur. This severe inflammation, however, is not able to clear H. pylori and the process may contribute to the associated disease pathogenesis. Toll-like receptor 2 (TLR2) and Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) might be essential for activation of innate immunity against H. pylori infections. Type 1 helper T cells and regulatory T cells induced in stomach and Peyers patches play an important role in the associated chronic inflammation. Recently, vaccines targeting various factors associated with H. pylori infection have been developed. This review provides information on the mechanisms of the host immune system response against H. pylori infections and the characteristics of H. pylori that enable it to evade host defenses.
Export Options
About this article
Cite this article as:
Ano Yasuhisa, Tsubone Hirokazu, Sakudo Akikazu and Fujiwara Daisuke, Mucosal Immune Regulation and Vaccines for Helicobacter-associated Gastritis, Current Chemical Biology 2010; 4 (3) . https://dx.doi.org/10.2174/2212796811004030219
DOI https://dx.doi.org/10.2174/2212796811004030219 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry Stem Cells, Cancer, Liver, and Liver Cancer Stem Cells: Finding a Way Out of the Labyrinth...
Current Cancer Drug Targets Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Annona sp: Plants with Multiple Applications as Alternative Medicine - A Review
Current Bioactive Compounds Current Status of Gene Therapy for Hepatocellular Carcinoma, with a Focus on Gene Delivery Approaches
Current Gene Therapy New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies
Current Medicinal Chemistry In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells
Current Cancer Drug Targets Gene Delivery for Cancer Therapy
Current Drug Delivery Delivery of siRNA to the Target Cell Cytoplasm: Photochemical Internalization Facilitates Endosomal Escape and Improves Silencing Efficiency, In Vitro and In Vivo
Current Pharmaceutical Design The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic Techniques for Pharmacogenetic Analyses
Current Pharmaceutical Design An Overview on Inventions Related to Ginger Processing and Products for food and Pharmaceutical Applications
Recent Patents on Food, Nutrition & Agriculture Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
Current Drug Targets Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
Current Diabetes Reviews Functionalized magnetic nanoparticles for biomedical applications
Current Pharmaceutical Design The Role of microRNA-126 in Vascular Homeostasis
Current Vascular Pharmacology Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies
Current Medicinal Chemistry